A promising breakthrough in cancer treatment is taking shape at the University of Missouri Research Reactor (MURR), where scientists are developing a powerful radioisotope that could one day precisely ...

Fewer than half of eligible patients with advanced ovarian cancer receive first-line maintenance treatments, highlighting ...

A study published by Caris showed that certain tumor types had very low or no HER2 overexpression, which has implications for biomarker testing strategies.

"I went to the doctor to have imaging done, and they found a massive tumor in my intestines. Life changed..." View Entire ...

Melanoma, the most serious skin cancer, claims thousands of lives yearly, with men dying at a higher rate due to delayed detection and treatment. Jim Crooks was shocked by his diagnosis, having no ...

Table of contents In A Nutshell Drug Shows Selective Activity Against Ovarian Cancer Why Single Drugs Fall Short Combination Therapy Shows Superior Results Exploiting Cancer’s Vulnerabilities ...

Long-term results from the phase 2 OVARIO trial (NCT03326193) highlight the effectiveness of niraparib plus bevacizumab as maintenance therapy in patients with advanced ovarian cancer.

There is little difference in how long women with advanced epithelial ovarian cancer (EOC) survive, whether they have chemotherapy or surgery first. There is probably little difference in how long it ...

Background: Pulmonary large-cell neuroendocrine carcinoma (PLCNEC) is a rare and highly aggressive subtype of lung cancer with neuroendocrine features, typically diagnosed at an advanced stage.

The incidence of neuroendocrine tumors is increasing, necessitating the need for more post-operative medical strategies. Available therapies and promising agents are discussed in this article.